Botulinum Neurotoxin Type A
Phase 2Small molecule
Botulinum Neurotoxin Type A is one of 8 small molecule programs targeting Spasticity. It is currently in Phase 2.
2
Indications
6
Total Trials
3
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Spasticity
#DrugCompanyPhaseTrials
1Lioresal
NovartisApproved
Namenda
AbbVieApproved
Zanaflex
LLegacy Health System
Approved
Cesamet
BBausch Health Americas, Inc.
Approved
IPN10200
IpsenPhase 2
Dysport
IpsenPhase 2
Botulinum Neurotoxin Type A
DDeNova Research
Phase 2
Corabotase
IpsenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Spasticity1 trial
Effectiveness of an Interprofessional Approach to the Treatment of Spasticity With Botulinum Toxin & Non-pharmacological Therapies
Not yet recruiting·—·N/A·NCT07160699·30 enrolled
Treatment1 trial
Study of the Drug B11-FC (Botulism Treatment)
Not yet recruiting·GGamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation·Phase 1/2·NCT06580236·40 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Botulinum Neurotoxin Type A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDeNova Research